MA54458A - Formes cristallines et formes salines d'un inhibiteur de kinase - Google Patents
Formes cristallines et formes salines d'un inhibiteur de kinaseInfo
- Publication number
- MA54458A MA54458A MA054458A MA54458A MA54458A MA 54458 A MA54458 A MA 54458A MA 054458 A MA054458 A MA 054458A MA 54458 A MA54458 A MA 54458A MA 54458 A MA54458 A MA 54458A
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline
- kinase inhibitor
- salt forms
- salt
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54458A true MA54458A (fr) | 2021-10-20 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054458A MA54458A (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12017995B2 (fr) |
| EP (1) | EP3894012A1 (fr) |
| JP (2) | JP7509779B2 (fr) |
| KR (1) | KR20210102381A (fr) |
| CN (1) | CN113329790A (fr) |
| AU (1) | AU2019395419A1 (fr) |
| BR (1) | BR112021011333A2 (fr) |
| CA (1) | CA3122840A1 (fr) |
| CL (1) | CL2021001537A1 (fr) |
| CO (1) | CO2021007613A2 (fr) |
| CR (1) | CR20210375A (fr) |
| GE (1) | GEP20247596B (fr) |
| IL (1) | IL283860A (fr) |
| MA (1) | MA54458A (fr) |
| MX (1) | MX2021006951A (fr) |
| PE (1) | PE20211757A1 (fr) |
| PH (1) | PH12021551356A1 (fr) |
| SG (1) | SG11202105949RA (fr) |
| WO (1) | WO2020123800A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019212801B2 (en) * | 2018-01-26 | 2024-07-04 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TW202208335A (zh) * | 2020-04-30 | 2022-03-01 | 美商艾克塞里克斯公司 | 製備激酶抑制劑之方法 |
| AU2021318134A1 (en) | 2020-07-31 | 2023-03-02 | Exelixis, Inc. | Combinations for the treatment of cancer |
| MX2023005273A (es) | 2020-11-05 | 2023-05-23 | Exelixis Inc | Composiciones farmaceuticas de un inhibidor de cinasa. |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| CA3240202A1 (fr) | 2021-12-22 | 2023-06-29 | Kirsten Phizackerley | Formes cristallines et formes salines d'un inhibiteur de kinase |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2651730T3 (es) * | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| AU2009303602B2 (en) | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| KR20210151988A (ko) | 2009-01-16 | 2021-12-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| MX370848B (es) | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
| CA2910278C (fr) | 2013-05-02 | 2021-09-28 | Anaptysbio, Inc. | Anticorps diriges contre la proteine de mort programmee 1 (pd-1) |
| WO2015123639A1 (fr) | 2014-02-14 | 2015-08-20 | Exelixis, Inc. | Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation, et méthodes d'utilisation |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| EP3630726B1 (fr) | 2017-05-26 | 2021-12-22 | Exelixis, Inc. | Forms solides et crystallines des sels de la n-{4-[(6,7-dimethoxyquinolein-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés pour leur préparation et leurs utilisations. |
| AU2019212801B2 (en) | 2018-01-26 | 2024-07-04 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| EP3976587A1 (fr) * | 2019-06-03 | 2022-04-06 | Exelixis, Inc. | Formes de sel cristallin d'un inhibiteur de kinase |
-
2019
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 EP EP19836338.4A patent/EP3894012A1/fr active Pending
- 2019-12-12 CA CA3122840A patent/CA3122840A1/fr active Pending
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 JP JP2021533537A patent/JP7509779B2/ja active Active
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 US US17/312,658 patent/US12017995B2/en active Active
- 2019-12-12 KR KR1020217021734A patent/KR20210102381A/ko unknown
- 2019-12-12 AU AU2019395419A patent/AU2019395419A1/en active Pending
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/fr active Application Filing
- 2019-12-12 MA MA054458A patent/MA54458A/fr unknown
-
2021
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-09 IL IL283860A patent/IL283860A/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP2024038167A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20247596B (en) | 2024-02-26 |
| JP2024038167A (ja) | 2024-03-19 |
| US12017995B2 (en) | 2024-06-25 |
| CO2021007613A2 (es) | 2021-06-21 |
| CR20210375A (es) | 2021-08-18 |
| IL283860A (en) | 2021-07-29 |
| PH12021551356A1 (en) | 2021-12-06 |
| SG11202105949RA (en) | 2021-07-29 |
| EP3894012A1 (fr) | 2021-10-20 |
| KR20210102381A (ko) | 2021-08-19 |
| MX2021006951A (es) | 2021-07-15 |
| BR112021011333A2 (pt) | 2021-08-31 |
| WO2020123800A1 (fr) | 2020-06-18 |
| CL2021001537A1 (es) | 2022-02-04 |
| JP2022512399A (ja) | 2022-02-03 |
| CA3122840A1 (fr) | 2020-06-18 |
| PE20211757A1 (es) | 2021-09-07 |
| AU2019395419A1 (en) | 2021-07-01 |
| JP7509779B2 (ja) | 2024-07-02 |
| CN113329790A (zh) | 2021-08-31 |
| TW202039440A (zh) | 2020-11-01 |
| US20230029213A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| AR114827A1 (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
| MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA46866A (fr) | Une forme cristalline d'un inhibiteur de magl | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
| MA50921A (fr) | Sels et formes cristallines d'un modulateur allostérique positif du gabaa | |
| MA41827A (fr) | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton | |
| MA56022A (fr) | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 | |
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| MA53671A (fr) | Formes cristallines d'un agoniste du récepteur farnésoïde x | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
| MA53546A (fr) | Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide | |
| IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
| MA54541A (fr) | Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase |